WO2026033456 - COMPOSITIONS COMPRISING ISOLATED ENDOTHELIAL PROGENITOR CELLS FOR TREATING VON WILLEBRAND DISEASE
National phase entry is expected:
Publication Number
WO/2026/033456
Publication Date
12.02.2026
International Application No.
PCT/IB2025/058044
International Filing Date
07.08.2025
Title **
[English]
COMPOSITIONS COMPRISING ISOLATED ENDOTHELIAL PROGENITOR CELLS FOR TREATING VON WILLEBRAND DISEASE
[French]
COMPOSITIONS COMPRENANT DES CELLULES PROGÉNITRICES ENDOTHÉLIALES ISOLÉES POUR LE TRAITEMENT DE LA MALADIE DE VON WILLEBRAND
Applicants **
THE UNIVERSITY OF QUEENSLAND
Inventors
HAMZA, Moayed
O'NEILL, Mark
PATEL, Jatin
KHOSROTEHRANI, Kiarash
SHAFIEE, Abbas
Priority Data
63/681,376
09.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP Australia
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5002 | |
| EPO | Filing, Examination, Granting | 77095 | |
| Japan | Filing, Examination, Granting | 4365 | |
| South Korea | Filing, Examination, Granting | 6493 | |
| USA | Filing, Examination, Granting | 36040 |
Total:
128,995
Contact Us
Abstract[English]
The present technology comprises isolated endothelial progenitor cell (EPC) populations and mesenchymal stem cell (MSC) populations, and methods of making and using the same for treating bleeding disorders, including Von Willebrand Disease, and associated symptoms.[French]
La présente technologie comprend des populations de cellules progénitrices endothéliales isolées (EPC) et des populations de cellules souches mésenchymateuses (MSC), et des procédés de fabrication et d'utilisation de celles-ci pour traiter des troubles hémorragiques, y compris la maladie de von Willebrand, et des symptômes associés.